|
1
|
Thai AA, Solomon BJ, Sequist LV, Gainor JF
and Heist RS: Lung cancer. Lancet. 398:535–554. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ettinger DS, Bepler G, Bueno R, Chang A,
Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis
FW Jr, et al: Non-small cell lung cancer clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 4:548–582. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takeda M, Okamoto I and Nakagawa K: Pooled
safety analysis of EGFR-TKI treatment for EGFR mutation-positive
non-small cell lung cancer. Lung Cancer. 88:74–79. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee WM: Acute liver failure in the United
States. Semin Liver Dis. 23:217–226. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sharma A, Mücke M and Seidman CE: Human
induced pluripotent stem cell production and expansion from blood
using a non-integrating viral reprogramming vector. Curr Protoc Mol
Biol. 122:e582018. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Corbett JL and Duncan SA: iPSC-derived
hepatocytes as a platform for disease modeling and drug discovery.
Front Med (Lausanne). 6:2652019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davidson MD, Ware BR and Khetani SR: Stem
cell-derived liver cells for drug testing and disease modeling.
Discov Med. 19:349–358. 2015.PubMed/NCBI
|
|
8
|
Park IH, Arora N, Huo H, Maherali N,
Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K and
Daley GQ: Disease-specific induced pluripotent stem cells. Cell.
134:877–886. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maehr R, Chen S, Snitow M, Ludwig T,
Yagasaki L, Goland R, Leibel RL and Melton DA: Generation of
pluripotent stem cells from patients with type 1 diabetes. Proc
Natl Acad Sci USA. 106:15768–15773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soldner F, Hockemeyer D, Beard C, Gao Q,
Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, et al:
Parkinson's disease patient-derived induced pluripotent stem cells
free of viral reprogramming factors. Cell. 136:964–977. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ellis J and Bhatia M: iPSC technology:
Platform for drug discovery. Point. Clin Pharmacol Ther.
89:639–641. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carpentier A, Nimgaonkar I, Chu V, Xia Y,
Hu Z and Liang TJ: Hepatic differentiation of human pluripotent
stem cells in miniaturized format suitable for high-throughput
screen. Stem Cell Res. 16:640–650. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Varghese DS, Alawathugoda TT and Ansari
SA: Fine tuning of hepatocyte differentiation from human embryonic
stem cells: Growth factor vs small molecule-based approaches. Stem
Cells Int. 2019:59682362019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Si-Tayeb K, Noto FK, Nagaoka M, Li J,
Battle MA, Duris C, North PE, Dalton S and Duncan SA: Highly
efficient generation of human hepatocyte-like cells from induced
pluripotent stem cells. Hepatology. 51:297–305. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hay DC, Zhao D, Fletcher J, Hewitt ZA,
McLean D, Urruticoechea-Uriguen A, Black JR, Elcombe C, Ross JA,
Wolf R and Cui W: Efficient differentiation of hepatocytes from
human embryonic stem cells exhibiting markers recapitulating liver
development in vivo. Stem Cells. 26:894–902. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao X and Liu Y: A transcriptomic study
suggesting human iPSC-derived hepatocytes potentially offer a
better in vitro model of hepatotoxicity than most hepatoma cell
lines. Cell Biol Toxicol. 33:407–421. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamaguchi T, Matsuzaki J, Katsuda T, Saito
Y, Saito H and Ochiya T: Generation of functional human hepatocytes
in vitro: Current status and future prospects. Inflamm Regen.
39:132019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ware BR, Berger DR and Khetani SR:
Prediction of drug-induced liver injury in micropatterned
co-cultures containing iPSC-derived human hepatocytes. Toxicol Sci.
145:252–262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou W, Graham K, Lucendo-Villarin B,
Flint O, Hay DC and Bagnaninchi P: Combining stem cell-derived
hepatocytes with impedance sensing to better predict human drug
toxicity. Expert Opin Drug Metab Toxicol. 15:77–83. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Okita K, Yamakawa T, Matsumura Y, Sato Y,
Amano N, Watanabe A, Goshima N and Yamanaka S: An efficient
nonviral method to generate integration-free human-induced
pluripotent stem cells from cord blood and peripheral blood cells.
Stem Cells. 31:458–466. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ballet F: Hepatotoxicity in drug
development: Detection, significance and solutions. J Hepatol. 26
(Suppl 2):S26–S36. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dirven H, Vist GE, Bandhakavi S, Mehta J,
Fitch SE, Pound P, Ram R, Kincaid B, Leenaars CHC, Chen M, et al:
Performance of preclinical models in predicting drug-induced liver
injury in humans: A systematic review. Sci Rep. 11:64032021.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takeda M, Okamoto I, Tsurutani J, Oiso N,
Kawada A and Nakagawa K: Clinical impact of switching to a second
EGFR-TKI after a severe AE related to a first EGFR-TKI in
EGFR-mutated NSCLC. Jpn J Clin Oncol. 42:528–533. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ho C, Davis J, Anderson F, Bebb G and
Murray N: Side effects related to cancer treatment: CASE 1.
Hepatitis following treatment with gefitinib. J Clin Oncol.
23:8531–8533. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sano E, Deguchi S, Sakamoto A, Mimura N,
Hirabayashi A, Muramoto Y, Noda T, Yamamoto T and Takayama K:
Modeling SARS-CoV-2 infection and its individual differences with
ACE2-expressing human iPS cells. iScience. 24:1024282021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Beigel JH, Tomashek KM, Dodd LE, Mehta AK,
Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, et
al: Remdesivir for the treatment of Covid-19-final report. N Engl J
Med. 383:1813–1826. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Axfors C, Schmitt AM, Janiaud P, van't
Hooft J, Abd-Elsalam S, Abdo EF, Abella BS, Akram J, Amaravadi RK,
Angus DC, et al: Mortality outcomes with hydroxychloroquine and
chloroquine in COVID-19 from an international collaborative
meta-analysis of randomized trials. Nat Commun. 12:23492021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Culy CR and Faulds D: Gefitinib. Drugs.
62:2237–2250. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cohen MH, Williams GA, Sridhara R, Chen G,
McGuinn WD Jr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R,
et al: United states food and drug administration drug approval
summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res.
10:1212–1218. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McKillop D, McCormick AD, Millar A, Miles
GS, Phillips PJ and Hutchison M: Cytochrome P450-dependent
metabolism of gefitinib. Xenobiotica. 35:39–50. 2005. View Article : Google Scholar : PubMed/NCBI
|
